ISC 2025 | RECAST-MT: RIC for acute ischemic stroke treated with mechanical thrombectomy

As we all know that the endovascular thrombectomy has been demonstrated to be the most effective therapy for acute eschemic stroke patients, secondary to large vessel occlusion. And all over the world the endovascular thrombectomy has been widely used in clinical practice but we can also encounter a lot of unfavorable functional outcomes in patients and the study has demonstrated that the mortality of these part of patients is about 15 to 20 percent in the 90 days and the functional dependence rate is about 40 to 50 percent. So how to improve how to further improve the functional outcomes of patients who achieved endovascular thrombectomy has been has been investigated and has also been gained attention in the field of acute ischemic stroke. And during the past years, a lot of researchers and clinical physicians has found that neuroprotective drugs and strategies and in combination with endovascular thrombectomy may be a promising therapy to further improve the functional outcome of the patients who achieved the endovascular thrombectom. And in our group we we researched the neuroprotective effects of remote ischemic conditioning, and we found that the neuroprotective or the cerebral protective of remote ischemic conditioning has been significantly. And in our pilot study of the remote ischemic conditioning in patients who were treated with a endovascular thrombectomy, we found that both bilateral occlusion didn’t significantly influence the cerebral hydrodynamics, or it also didn’t influence the intracranial pressure. So based on our previous preclinical and clinical pilot study, and now we are conducting large center clinical trial in China, and the trial is RECAST-MT. And in this trial, we want to investigate and to determine the safety and efficacy of remote ischemic conditioning in patients with anterior circulation acute ischemia stroke who were treated with endovascular stombectomy within 24 hours. And in this study we have two main goals, the first is to determine the efficacy of remote ischemia conditioning and the other the other aim is to determine whether two weeks of remote ischemic conditioning treatment is as effective as one month remote ischemic conditioning treatment. So in this study we designed three groups and one group is a control group and this group of patients will receive endovascular thrombectomy alone and there are also two other groups and one group received 14 days of remote ischemic condition treatment and the other group received 30 days remote ischemic condition treatment. And the difference with other similar studies that investigate the remote ischemic condition in patients who received an endovascular thrombectomy and in the RECAST-MT study we initiated remote ischemic conditioning before the treatment of endovascular thrombectomy and in combination with endovascular thrombectomy. And so the main difference between our study and previous studies may be located in our study performed remote ischemic conditioning before the before the large vessel was recanalized. This may be a more important target than for the cerebral protection that before the vessel recanalized and neuroprotection may slow down the cognitive function progress to preserve or freeze much more penumbra and which can pave the way for endovascular thrombectomy. And now the study has been begun and we have recruited about 100 patients in China and we hope that the study can be complete in recruitment in the following two years which will recruit the patients about 2,100 participants in China.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.